FRI0179 PREDICTION OF RESPONSE TO RITUXIMAB IN SLE USING A VALIDATED TWO-SCORE SYSTEM FOR INTERFERON

摘要: Background: Rituximab (RTX) is used for resistant SLE but clinical response varies. We previously validated two interferon-stimulated gene expression scores (IFN-Score-A and IFN-Score-B) that improved prediction of outcomes in SLE. IFN-Score-A included most commonly reported ISGs predicted flares glucocorticoid requirements. IFN-Score-B respond to multiple IFN subtypes development At-Risk individuals. Diagnosis was associated with both scores, while only elevated RA. The British Society Rheumatology Biologics Registry (BILAG-BR) collects samples RTX-treated patients the UK. MASTERPLANS a consortium identify predictors drug response. Objectives: To investigate whether predict BILAG RTX at 6 months. Methods: This preliminary analysis first BILAG-BR complete data. Patients were recruited if they starting cycle active (BILAG A or 2xBILAG B) despite previous cyclophosphamide mycophenolate mofetil. Disease activity measured using BILAG-2004. Clinical defined as improvement by >=1 grade BILAG-2004 systems no worsening other systems. Whole blood collected into TEMPUS tubes RNA extracted. IFN-Scores custom Taqman array described [El Sherbiny et al., 2018]. Multivariate logistic regression test baseline covariates Results: Samples available from 147 patients, whom 84 had month data this analysis. 40/84 (47.6%) In univariate multivariate analysis, high significantly (see table 1). Conclusion: suggests assessment has role predicting RTX. novel score (Score more predictive than classic A). These results add body work showing predicts clinically significant independently overall activity. Future will analyse biomarker larger cohort integrate putative biological Reference: [1] El-Sherbiny, Y. M.… E. M. Vital (2018). Sci. Rep. 8: 5793. Acknowledgement: would like thank Medical Research Council, National Institute Health Research, UK funding project. Disclosure Interests: Adewonuola Alase: None declared, Zoe Wigston: Agata Burska: Elizabeth Hensor: Md Yuzaiful Yusof: John Reynolds: Masterplans Consortium: Miriam Wittmann Consultant for: consultancy honoraria Abbvie, Celgene, Janssen, L’Oreal, Novartis Pfizer, Ian N. Bruce Grant/research support from: Genzyme Sanofi, GlaxoSmithKline, AstraZeneca, Eli Lilly, ILTOO Pharma, MedImmune, Merck Serono, Speakers bureau: UCB Edward He received research grant Roche, GSK AstraZeneca.